Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Completed Not applicable Interventional Results available

Low Field Magnetic Stimulation for Treatment Resistant Depression

NCT01944644
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active Low Field Magnetic Stimulation, Sham Low Field Magnetic Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional

Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness

NCT05491538
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Stress Disorder, Post-Traumatic
Interventions
Social Cognition and Interaction Training-Work Edition (SCIT-WE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serum Markers as a Bioassay for Unipolar Depression

NCT00825799
View directory record Official record
Conditions
Major Depression
Interventions
Not listed
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 3, 2014 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Phase 4 Interventional

Aβ Dynamics in LLMD

NCT05004987
View directory record Official record
Conditions
Alzheimer Disease, Major Depressive Disorder
Interventions
Escitalopram Oxalate, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

NCT01263093
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Clopidogrel, LY2216684
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

NCT01121484
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained-release, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 13, 2026, 9:24 AM EDT
Active, not recruiting Phase 2 Interventional

Combination of Novel Therapies for CKD Comorbid Depression

NCT04422652
View directory record Official record
Conditions
Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions
Bupropion, Behavioral activation therapy, Placebo, Clinical Management
Drug · Behavioral · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Stony Brook, New York • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Active, not recruiting Phase 3 Interventional

An Open-Label Study of Azetukalner in Major Depressive Disorder

NCT06922110
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Azetukalner
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
69
States / cities
Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Assessing Symptomatic Clinical Episodes in Depression

NCT03595579
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AXS-05, Bupropion
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants

NCT01380691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo-matching LY2216684, Placebo-matching alcoholic beverage, Alcoholic beverage
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 13, 2026, 9:24 AM EDT
Terminated Phase 3 Interventional

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional

Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments

NCT06976840
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Intermittent theta burst stimulation, Sham theta burst stimulation, Continuous theta burst stimulation
Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional

CARED : A Novel Rapid Treatment Paradigm for Depression

NCT07507370
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Intermittent Theta Burst Stimulation (iTBS), Transcranial Alternating Current Stimulation (tACS), Psychotherapy, Sham (Placebo) Transcranial Alternating Current Stimulation (tACS)
Device · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 1 Interventional Results available

Closed-loop Optimized rTMS for Depression

NCT04142320
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Neuronavigated rTMS, sham rTMS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Not listed Not applicable Interventional

Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)

NCT03012724
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
H7-Coil, H1-Coil
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Juno Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression

NCT04138680
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active Biofeedback, Sham Biofeedback
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Correlates of Stress and Perceived Control in Adolescent Depression

NCT04788524
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Computer Task Manipulation
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT04985942
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Glendale, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

NCT02484456
View directory record Official record
Conditions
Major Depression
Interventions
AV 101 (4-Chlorokynurenine), Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 13, 2026, 9:24 AM EDT
Terminated Phase 4 Interventional Results available

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

NCT00429169
View directory record Official record
Conditions
Depression
Interventions
Paroxetine, Bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 13, 2026, 9:24 AM EDT
Completed Phase 2 Interventional

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

NCT06384157
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
INDV-2000, Placebo
Drug · Other
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
35
States / cities
Hamilton, Alabama • Phoenix, Arizona • Oceanside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 13, 2026, 9:24 AM EDT
Terminated Not applicable Interventional

Pharmacogenomic Testing in Major Depressive Disorder

NCT03228953
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pharmacogenomic testing
Other
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 13, 2026, 9:24 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

NCT07610473
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
DT-101, Placebo
Drug
Lead sponsor
Draig Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 13, 2026, 9:24 AM EDT